Juno Therapeutics Inc (NASDAQ:JUNO) announced that it has defeated an attempt to invalidate a patent exclusively licensed by Juno that covers, among other …
Juno Therapeutics Inc (NASDAQ:JUNO) provided an update of key data from studies of its investigational chimeric antigen receptor (CAR) T cell product candidates, …
Maxim analyst Jason McCarthy provides insight on Juno Therapeutics Inc (NASDAQ:JUNO) amid the hold placed on the firm’s JCAR015 ROCKET study, which arose …
Juno Therapeutics Inc (NASDAQ:JUNO) announced encouraging preliminary clinical data for JCAR017 in patients with relapsed or refractory (r/r) aggressive non-Hodgkin lymphoma (NHL) in …
Juno Therapeutics Inc (NASDAQ:JUNO) shares are falling 4% after last week’s hit: the firm’s pivotal ROCKET trial of JCAR015, a product candidate in …
Shares of Juno Therapeutics Inc (NASDAQ:JUNO) fall as Wall Street continues to debate the unexpected patient deaths and clinical hold for the company’s Phase …
In a research report published Wednesday, Maxim analyst Jason McCarthy reiterated a Buy rating on shares of Juno Therapeutics Inc (NASDAQ:JUNO), while reducing …
J.P.
Wednesday turned out to be a nightmare for Juno Therapeutics Inc (NASDAQ:JUNO) investors, after the drug maker disclosed that it has voluntarily placed on hold …
Juno Therapeutics Inc (NASDAQ:JUNO) reported financial results and business highlights for the third quarter 2016. “JCAR017, a key product candidate of our CD19 …
